Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$72.00K$72.00K−26.5% vs Q1 2023 Net Income-$48.54M-$48.54MN/M vs Q1 2023 EPS Diluted-$0.79-$0.79N/M vs Q1 2023 Operating Income-$55,897,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$45,223,000N/M Margins · derivedOperating margin-77634.7%−3682.7 pt vs Q1 2023
Net margin-67419.4%+2122.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end